SUPN — Supernus Pharmaceuticals, Inc.

Is SUPN overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Drug Manufacturers - Specialty & Generic

Oversold As of October 3, 2026

Supernus Pharmaceuticals, Inc. (SUPN) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Drug Manufacturers - Specialty & Generic) last closed at $42.38. The rating moved from Strong Oversold to Oversold on October 2, 2026.

See all oversold Healthcare stocks →

AI analysis

Supernus Pharmaceuticals, Inc. (SUPN) is a specialty CNS-focused drug developer and commercial-stage seller with a concentrated but recurring revenue base. Near-term outlook is balanced: steady cash flows from marketed therapies provide defensive characteristics, while pipeline and late-stage assets offer upside if clinical/regulatory milestones are met. Headwinds include payer pricing pressure tied to ongoing policy focus on drug affordability, the risk of generic competition, and heightened macro/market risk that can compress multiples and delay financing. Absent a clear upcoming clinical or regulatory catalyst, expect limited directional conviction in the short term with modest upside potential over a one-month horizon if positive news or supportive investor flows emerge.

Key factors

  • Established specialty CNS commercial franchise providing recurring revenue and relative defensive demand versus broader biopharma cyclicality
  • Concentration of revenue in a small number of marketed products, which supports near-term cash flow but raises single-product exposure
  • Pipeline and late-stage assets that could provide upside if clinical readouts or approvals succeed, supporting medium-term growth optionality
  • Favorable investor appetite for select specialty pharma and late-stage biologics can support valuation re-rating when catalysts appear
  • Current market environment is risk-off with flows into defensive sectors, which may limit near-term upside absent clear new catalysts
  • Balance sheet and cash generation assumptions appear adequate for near-term operations but could constrain faster expansion or large M&A

Risks

  • Policy and payer pressure (Medicare drug-price negotiation / IRA) that could compress pricing and limit revenue for higher-cost therapies
  • Patent expirations or generic entrants on key CNS products could materially reduce sales concentration and margins
  • High dependence on a limited product set and potential for negative clinical/regulatory events to sharply affect revenue
  • Broader macro risk and risk-off market sentiment which can depress specialty pharma multiples and IPO/financing windows
  • Competitive pressure within CNS and adjacent therapeutic areas from branded competitors or novel mechanisms
  • Liquidity/financing risk if pipeline investments require funding during periods of weak capital markets

See today's live rating, score and targets

Members see the live hourly rating for SUPN — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.